Filtros de búsqueda

Lista de obras de Valeria Santini

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

artículo científico publicado en 2013

A selective activity of DNMTi decitabine on AML1ETO positive cells?

artículo científico publicado en 2007

A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.

artículo científico publicado en 2012

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

scientific article published on 01 July 2019

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

scientific article published on 28 January 2014

Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.

artículo científico publicado en 2011

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

scientific article published on 17 February 2020

Activity of vinorelbine on B-chronic lymphocytic leukemia cells in vitro

artículo científico publicado en 1999

Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5

artículo científico publicado el 1 de agosto de 1991

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

artículo científico publicado en 2018

Amifostine in the treatment of low-risk myelodysplastic syndromes.

artículo científico publicado en 2000

Amifostine: chemotherapeutic and radiotherapeutic protective effects

artículo científico publicado en 2001

Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.

artículo científico publicado en 1997

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

artículo científico publicado en 2016

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

artículo científico publicado en 2018

Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia

artículo científico publicado en 1993

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

artículo científico publicado en 2010

Azacitidine in lower-risk myelodysplastic syndromes

scientific article published on December 2009

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

artículo científico publicado en 2009

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.

scientific article published on April 2009

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2014

Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells

scientific article published on 01 June 1998

Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.

artículo científico publicado en 2005

Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.

artículo científico publicado en 2003

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

artículo científico publicado en 2013

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

artículo científico publicado en 2001

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

scientific article published on 21 December 2018

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

artículo científico publicado en 2010

Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.

artículo científico

Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium

artículo científico publicado en 1988

Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias

artículo científico publicado en 1998

Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.

artículo científico publicado en 2007

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2011

Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9.

artículo científico publicado en 2013

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

artículo científico publicado en 2010

Defeating anaemia in myelodysplastic syndromes: another step forward

artículo científico publicado en 2017

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

artículo científico publicado en 2014

Dependence of leukemic cell autofluorescence patterns on the degree of differentiation ⬇️

artículo científico publicado el 1 de octubre de 2003

Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation

scientific article published on 01 May 1996

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet

artículo científico publicado en 2018

Differentiation therapy of myelodysplastic syndromes: fact or fiction?

artículo científico publicado en 1998

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

scientific article published on 06 September 2018

Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.

artículo científico publicado en 2012

Effect of (dl)-5-methyltetrahydrofolate on acute non-lymphocytic leukemia cells in primary culture

artículo científico publicado en 1991

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes

artículo científico publicado en 2010

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

artículo científico publicado en 1996

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

artículo científico publicado en 2017

Enasidenib: a magic bullet for myelodysplastic syndromes?

scientific article published on 05 March 2020

Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.

artículo científico

Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

artículo científico publicado en 2004

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

artículo científico publicado en 2013

FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.

artículo científico publicado en 2003

Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.

artículo científico publicado en 2001

Functional and structural interactions between osteoblastic and preosteoclastic cells in vitro

artículo científico publicado en 1995

Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia

artículo científico publicado en 1997

Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia

artículo científico publicado en 1997

Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors

artículo científico publicado en 2011

Hemolymphangiomatosis of the spleen: imaging features.

artículo científico publicado en 2005

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML

scientific article published on 19 July 2018

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

artículo científico publicado en 2012

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

artículo científico publicado en 2007

Homoharringtonine: history, current research, and future direction

artículo científico publicado en 2001

How I treat MDS after hypomethylating agent failure

scientific article published on 13 December 2018

Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells

artículo científico publicado en 2012

Hypomethylating agents and chemotherapy in MDS.

artículo científico

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

artículo científico publicado en 2018

Immunohistochemistry applied to the study of bone marrow Gaucher's cells: a case report

scientific article published on 01 January 1999

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

artículo científico publicado en 2017

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

scientific article published on 13 July 2020

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

artículo científico publicado en 2020

In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

artículo científico publicado en 2012

In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.

artículo científico publicado en 2003

Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells

scientific article published on 01 October 1999

Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate

artículo científico publicado en 1989

Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid.

artículo científico publicado en 1991

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

artículo científico publicado en 2008

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial

scientific article published on 24 March 2020

Iron overload and chelation therapy in myelodysplastic syndromes.

artículo científico

Is survival enough for myelodysplastic syndromes?

artículo científico publicado en 2009

Life after hypomethylating agents in myelodysplastic syndrome: new strategies

artículo científico publicado en 2015

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

scientific article published on 01 January 2020

Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647.

artículo científico publicado en 2002

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

artículo científico

Maturation and apoptosis of primary human acute myeloblastic leukemia cells are determined by TNF-alpha exclusively through CD120A stimulation

artículo científico publicado en 1999

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

artículo científico publicado en 2014

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

artículo científico publicado en 2011

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2014

Natural fluorescence imaging of leukemic cells for studying uptake and retention of anthracyclines

artículo científico publicado en 1999

Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.

artículo científico publicado en 2012

No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?

artículo científico publicado en 2004

Novel therapeutic strategies: hypomethylating agents and beyond.

artículo científico

Of blood and bone: the sotatercept adventure

artículo científico publicado en 2018

On raising the "dust of blood": from unrevealing thrombopoiesis to treatment of thrombocytopenias with thrombomimetic drugs

artículo científico publicado en 2014

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

artículo científico publicado en 2017

Outcome of therapy-related myeloid neoplasms treated with azacitidine

artículo científico publicado en 2012

P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC)

P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA)

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2018

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

artículo científico publicado en 2019

Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance

artículo científico publicado en 2007

Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF ⬇️

artículo científico publicado el 1 de noviembre de 1991

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

artículo científico publicado en 2018

Proliferation and cell loss of human leukemic cell subpopulations in liquid culture.

artículo científico publicado en 1988

Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.

artículo científico publicado en 2012

Pure red cell aplasia in autoimmune polyglandular syndrome with T lymphocytosis

artículo científico publicado en 1998

Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method

scientific article published on 01 November 1995

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

artículo científico publicado en 2016

Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.

artículo científico publicado en 2013

Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity.

artículo científico publicado en 1999

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

artículo científico publicado en 2011

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

artículo científico publicado en 2015

Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial

artículo científico publicado en 2018

Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells.

artículo científico publicado en 1988

Searching for the magic bullet against cancer: the butyrate saga

artículo científico publicado en 2001

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

artículo científico publicado en 1999

Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia

artículo científico publicado en 1995

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

scientific article published on 18 June 2020

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

artículo científico publicado en 2015

Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).

artículo científico publicado en 1990

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

scientific article published on 11 January 2019

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

artículo científico publicado en 2008

The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal.

artículo científico publicado en 2003

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.

artículo científico publicado en 2008

The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).

artículo científico publicado en 2011

The potential of amifostine: from cytoprotectant to therapeutic agent

artículo científico publicado en 1999

The quest for the perfect MDS scoring system

artículo científico publicado en 2011

The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.

artículo científico publicado en 1993

Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins

artículo científico publicado en 2012

Treatment of myelodysplastic syndrome with thrombomimetic drugs

artículo científico publicado en 2014

Treatment options in myelodysplastic syndromes: a new frontier.

artículo científico publicado en 2008

Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia

scientific article published on 01 October 1991

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

artículo científico publicado en 2017

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

artículo científico publicado en 2009

Why methylation is not a marker predictive of response to hypomethylating agents.

scientific article published on April 2014

[GM-CSF: its clinical administration; the treatment of aplasia]

artículo científico publicado en 1989

[Identification of myelodysplastic syndromes patients]

artículo científico publicado en 2014

Eficacia de la azacitidina en comparación con los regímenes de atención convencionales en el tratamiento de los síndromes mielodisplásicos de mayor riesgo: un estudio de fase III, aleatorizado, abierto

artículo científico publicado en 2009

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda